Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2015-05-12

Clinical Trial Update: Efficacy Study of Ambrisentan in Chinese Patients With Pulmonary Arterial Hypertension (PAH) [Phase 3]

View source ↗

Summary

Phase 3 efficacy study of ambrisentan in Chinese patients with pulmonary arterial hypertension has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • LETAIRIS (ambrisentan)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Vascular Disease | Phase 3 | Status: COMPLETED | Results posted: 2015-05-12